Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Other 1

Conditions

Weight Loss 1Sarcopenia 1Postoperative Complications 1Obesity 1Muscle Weakness 1Intermittent Fasting 1Esophageal Neoplasms 1Colorectal Neoplasms 1

Interventions

Oxaliplatin 135Fluorouracil 129Gemcitabine 116Bevacizumab 113Specimen Handling 103Leucovorin 101Capecitabine 88Magnetic Resonance Spectroscopy 82pembrolizumab 81Cisplatin 76Nivolumab 72Irinotecan 68130-nm albumin-bound paclitaxel 59Cetuximab 58durvalumab 57Paclitaxel 57Biopsy 56atezolizumab 43Radiotherapy 40Albumin-Bound Paclitaxel 37Taxes 36Carboplatin 35Folfox protocol 34lenvatinib 29Drug Therapy 28Cyclophosphamide 27sintilimab 26dehydroftorafur 26Radiation 26tislelizumab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Caloric Restriction × Gastrointestinal × 90 days × Clear all
NCT03676478 2026-06-08

EFECTS

University Hospital, Gasthuisberg

Phase NA Terminated
239 enrolled
Gastrointestinal

Esophageal Neoplasms, Postoperative Complications, Muscle Weakness, Sarcopenia

NCT05114798 2026-05-22

Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers

University of Illinois at Chicago

Phase NA Active not recruiting
193 enrolled
GastrointestinalOther

Intermittent Fasting, Obesity, Colorectal Neoplasms, Weight Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡